Cancer, a global health crisis, affects countless individuals worldwide, and surgery often becomes a crucial step in their journey. While surgeons aim to remove tumors entirely, leaving healthy tissues intact, the challenge lies in accurately identifying what needs to be excised. Various tools and techniques have evolved to assist in this delicate process, and visual imaging methods, such as fluorescent dyes, have proven invaluable.
However, a significant drawback arises when certain probes activate in healthy tissues due to endogenous enzymes, creating background fluorescence that obscures the target. Conversely, cancer cells may remain unmarked, leading to potential recurrence.
Enter the innovative work of our research group, which has addressed this shortcoming by developing a novel method to illuminate cancer cells within the body. In mouse trials, we introduced a specialized enzyme to tumors and employed a fluorescence probe that only activates in the presence of this unique enzyme.
Ryosuke Kojima, an Associate Professor at the University of Tokyo's Laboratory of Chemical Biology and Molecular Imaging, explains: "Older probes often mistakenly light up healthy tissue, creating background noise. Our highly selective, or bioorthogonal, dye probe remains inactive unless it encounters its matching engineered enzyme. We trained this enzyme through repeated mutation and selection, a form of directed evolution, to ensure it could activate the probe effectively within living organisms."
Kojima, alongside Professor Yasuterer Urano and their team, created a fluorescent probe resistant to activation by natural enzymes, reducing unwanted background glow. This probe was paired with a tailored reporter enzyme designed to activate it, resulting in fluorescence primarily where the enzyme is delivered. When tested on mice with peritoneal cancer, the engineered enzyme reached the tumors in the abdominal wall lining, and the probe illuminated as expected.
"This approach allowed us to visualize tiny, millimeter-sized tumor lesions with minimal background noise, offering a high level of contrast that could greatly benefit surgical procedures," Kojima stated. "In the short term, this system could serve as a powerful research tool, and in the long run, it may assist surgeons in more complete tumor removal by clearly identifying cancer cells. A key challenge for clinical use is ensuring the engineered enzyme does not provoke an unwanted immune response in patients."
The system's adaptability extends beyond peritoneal cancer, as many cancers present corresponding antigens, unique markers of tumor tissue. By adjusting the tumor-targeting component, such as an antibody or nanobody against a specific antigen, the same enzyme-probe pair could, in theory, be redirected to target other cancer types.
Looking ahead, this research opens doors to highly targeted drug delivery, where cancer-fighting drugs could be precisely guided to their intended sites, minimizing off-target effects. However, as Kojima emphasizes, this technology is still in its infancy, with trials thus far limited to mice. Much work remains before it can be deemed safe for human trials.
And this is where the controversy begins. With such promising results, how soon should we push for human trials? What potential risks might we overlook in our eagerness for a breakthrough? These are questions that demand careful consideration and open discussion. What are your thoughts? Feel free to share your opinions and insights in the comments below!
